Navigation Links
'Tumor Paint' Research Of Pediatric Oncologist Jim Olson Featured In Short Film -- A Sundance Festival Semifinalist

SEATTLE, Nov. 27, 2012 /PRNewswire/ -- A three-minute film about a tiny molecule that lights up brain tumors so neurosurgeons can better distinguish cancer from normal tissue has a chance to get its own moment in the spotlight as a semifinalist in the Sundance Film Festival in January.

"Bringing Light," ( which focuses on the "Tumor Paint" research led by James Olson, M.D., Ph.D., a clinical researcher at Fred Hutchinson Cancer Research Center and a pediatric oncologist at Seattle Children's Hospital, is available online for viewing and voting. Viewers have until Dec. 20 to cast their votes.

The film, directed by Bert Klasey, Chris Baron and James Allen Smith, also features neurosurgeon Richard Ellenbogen, M.D., chairman of the Department of Neurosurgery at the University of Washington School of Medicine, among others. It is part of a filmmaker competition called "Short Films, Big Ideas" sponsored by Focus Forward Films. Out of 30 total entries, five finalists will be screened at Sundance 2013 and the grand-prize winner will receive $100,000.

Olson's team developed Tumor Paint by re-engineering scorpion venom (chlorotoxin), which naturally targets brain cancer cells, by tagging it with a molecule that acts like a flashlight, causing brain tumors to "light up" during surgery so the margins can be seen more easily. The goal is to help surgeons remove as much cancer as possible while safely leaving normal brain tissue intact.

Tumor Paint is not yet in human use but is being developed by Blaze Bioscience, a Seattle biotech founded by Olson and Heather Franklin, president and CEO.

The potential of Tumor Paint is not limited to brain tumors; it has been found in preclinical studies to light up prostate, colon, breast and other cancers.  It is anticipated that human trials in cancer patients will begin next year.

If the human clinical trial results match the laboratory studies, Tumor Paint will enable surgeons to distinguish cancer tissue from non-cancerous tissue in real time as they operate. The ultimate goal is to save lives while also reducing problems caused by surgical removal of normal tissue in critical areas.

Another potential use for Tumor Paint is early detection of various forms of skin cancer. Olson and colleagues have demonstrated that it can light up non-pigmented skin cancers, which are sometimes difficult to detect and pose a greater threat to the patient if they are not detected early.

Olson gratefully points out that none of this research would have been possible without the support of private donors. "The work on Tumor Paint was funded primarily through financial gifts made to Fred Hutch and Seattle Children's Hospital by individuals, families and businesses that place their trust in our researchers to invent and develop new lifesaving therapies," he said.

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer with minimal side effects. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first and largest cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Private contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs. For more information visit or follow Fred Hutch on Facebook, Twitter or YouTube.

This news release was issued on behalf of Newswise™. For more information, visit

Media Contacts:
Kristen Woodward

SOURCE Fred Hutchinson Cancer Research Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market is Expected to Reach USD 7.9 billion by 2018: Transparency Market Research
2. Protein that helps tumor blood vessels mature could make cancer drugs more effective
3. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
4. Novocureā„¢ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
5. First targeted and programmable nanomedicine to show clinical antitumor effects published
6. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
7. bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
8. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
9. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
10. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
11. Nano-infused paint can detect strain
Post Your Comments:
(Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMISā„¢ technology, modifications ...
Breaking Biology Technology:
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:
(Date:10/6/2015)... Oct. 6, 2015  Maverix Biomics, Inc., a ... to its software portfolio with the debut of ... differential expression in eukaryotes. The software is integrated ... cloud-based genomic analysis solution that leverages proven open-source ... next-generation sequencing efforts. Garry Nolan,s ...
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... is excited to be named one of the first 100 ... announcement was recently made at an invite-only IBM Watson: ... Francisco , where iDAvatars presented a demo of its ... "It is both an honor and a privilege to be ... the cognitive power of IBM Watson in our product, which ...
Breaking Biology News(10 mins):
... RIVERSIDE, Calif. With the Easter holiday season coming up ... hens in egg farms producing the maximum number of eggs they ... can reduce egg production by five percent or more," says ... the University of California, Riverside. "One way to boost egg ...
... 2011 Stanford University professor Axel T. Brunger has ... Biochemistry and Molecular Biology,s inaugural DeLano Award for Computational ... Structural Biology with Single Molecules" at 9:03 a.m. on ... at the Walter E. Washington Convention Center in Washington, ...
... Mass. A single change to even one of the ... the human genome can result in severe diseases such as ... minor change in the DNA of a virus or bacteria ... for physicians to treat with standard drug therapies. For these ...
Cached Biology News:
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Synaptotagmin, phosphoSer309...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: